What’s in Apollo Endosurgery, Inc. (APEN) After Today’s Huge Decline?

December 11, 2017 - By Ellis Scott

The stock of Apollo Endosurgery, Inc. (NASDAQ:APEN) is a huge mover today! The stock decreased 7.33% or $0.33 during the last trading session, reaching $4.17. About 91,114 shares traded. Apollo Endosurgery, Inc. (NASDAQ:APEN) has declined 51.87% since December 11, 2016 and is downtrending. It has underperformed by 68.57% the S&P500.
The move comes after 5 months negative chart setup for the $72.10 million company. It was reported on Dec, 11 by Barchart.com. We have $3.88 PT which if reached, will make NASDAQ:APEN worth $5.05 million less.

Analysts await Apollo Endosurgery, Inc. (NASDAQ:APEN) to report earnings on March, 14. They expect $-0.29 EPS, up 99.17 % or $34.72 from last year’s $-35.01 per share. After $-0.32 actual EPS reported by Apollo Endosurgery, Inc. for the previous quarter, Wall Street now forecasts -9.38 % EPS growth.

More notable recent Apollo Endosurgery, Inc. (NASDAQ:APEN) news were published by: Businesswire.com which released: “Apollo Endosurgery Provides Update and Clarity to FDA Letter to Health Care …” on August 11, 2017, also Businesswire.com with their article: “Apollo Endosurgery Receives FDA Clearance for OverStitchâ„¢ Sx Endoscopic …” published on November 27, 2017, Seekingalpha.com published: “Apollo Endosurgery’s (APEN) CEO Todd Newton on Q3 2017 Results – Earnings Call …” on October 28, 2017. More interesting news about Apollo Endosurgery, Inc. (NASDAQ:APEN) were released by: Businesswire.com and their article: “Apollo Endosurgery, Inc. Reports First Quarter 2017 Results” published on May 04, 2017 as well as Businesswire.com‘s news article titled: “David C. Pacitti Joins Apollo Endosurgery Board of Directors” with publication date: November 16, 2017.

Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices for the treatment of obesity. The company has market cap of $72.10 million. The firm offers endo-bariatric products, such as Orbera intragastric balloon system, a non-surgical alternative for the treatment of overweight and obese adults; and OverStitch, an endoscopic suturing system that enables endoscopic procedures by allowing physicians to place full-thickness sutures and secure the approximation of tissue through an Olympus dual-channel flexible endoscope. It currently has negative earnings. It also provides surgical products, including Lap-Band system, a system designed to provide minimally invasive long-term treatment of obesity; and accessories used in laparoscopic bariatric surgeries.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.